Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma

Journal of Investigative Dermatology

Volumn 126, Issue 1, 2006, Pages 154-160

  Goel, Vikas K ^a,b   Lazar, Alexander J F ^b,c,d   Warneke, Carla L ^d   Redston, Mark S ^b,c   Haluska, Frank G ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; EXON; FEMALE; GENE ACTIVATION; GENE INACTIVATION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MUTATIONAL ANALYSIS; ONCOGENE N RAS; PREVALENCE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SKIN; STATISTICAL SIGNIFICANCE; THICKNESS; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, RAS; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; SKIN NEOPLASMS;

EID: 33644774541     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/sj.jid.5700026     Document Type: Article

References (31)

1. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R et al. (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997-7000
2. Chang DZ, Panageas KS, Osman I, Polsky D, Busam K, Chapman PB (2004) Clinical significance of BRAF mutations in metastatic melanoma. J Transl Med 2:46
3. Collisson EA, De A, Suzuki H, Gambhir SS, Kolodney MS (2003) Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. Cancer Res 63:5669-73
4. Daniotti M, Oggionni M, Ranzani TV, Vallacchi V, Campi V, Di Stasi D et al. (2004) BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 23:5968-77
5. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-54
6. Davison JM, Rosenbaum E, Barrett TL, Goldenberg D, Hoque MO, Sidransky D et al. (2005) Absence of V599E BRAF mutations in desmoplastic melanomas. Cancer 103:788-92
7. Dhawan P, Singh AB, Ellis DL, Richmond A (2002) Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res 62:7335-42
8. Guldberg P, thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J (1997) Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 57:3660-3
9. Haluska FG, Hodi FS (1998) Molecular genetics of familial cutaneous melanoma. J Clin Oncol 16:670-82
10. Haluska FG, Multani PS (1999) Melanoma. In: Cancer Chemotherapy and Biological Response Modifiers (Pinedo HM, Longo DL and Chabner BA, eds). Amsterdam: Elsevier Science, 146-64
11. Kumar R, Angelini S, Hemminki K (2003) Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9. Oncogene 22:9217-24
12. Maldonado JL, Fridlyand J, Pate H, Jain AN, Busam K, Kageshita T et al. (2003) Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95:1878-90
13. Mutter GL, Ince TA, Baak JP, Kust GA, Zhou XP, Eng C (2001) Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 61:4311-4
14. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J (2003) NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 9:6483-8
15. Poetsch M, Dittberner T, Woenckhaus C (2001) PTEN/MMAC1 in malignant melanoma and its importance for tumor progression. Cancer Genet Cytogenet 125:21-6
16. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM et al. (2003) High frequency of BRAF mutations in nevi. Nat Genet 33:19-20
17. Saldanha G, Purnell D, Fletcher A, Potter L, Gillies A, Pringle JH (2004) High BRAF mutation frequency does not characterize all melanocytic tumor types. Int J Cancer 111:705-10
18. Sasaki Y, Niu C, Makino R, Kudo C, Sun C, Watanabe H et al. (2004) BRAF point mutations in primary melanoma show different prevalences by subtype. J Invest Dermatol 123:177-83
19. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL et al. (2003) Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63:756-9
20. Shinozaki M, Fujimoto A, Morton DL, Hoon DS (2004) Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 10:1753-7
21. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M et al. (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965-72
22. Thomas NE, Alexander A, Edmiston SN, Parrish E, Millikan RC, Berwick M et al. (2004) Tandem BRAF mutations in primary invasive melanomas. J Invest Dermatol 122:1245-50
23. Tsao H, Goel V, Wu H, Yang G, Haluska FG (2004) Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 122:337-41
24. Tsao H, Mihm Jr MC, Sheehan C (2003) PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma. J Am Acad Dermatol 49:865-72
25. Tsao H, Zhang X, Benoit E, Haluska FG (1998) Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 16:3397-402
26. Tsao H, Zhang X, Fowlkes K, Haluska FG (2000) Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 60:1800-4
27. Uribe P, Wistuba II, Gonzalez S (2003) BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol 25:365-70
28. Wu H, Goel V, Haluska FG (2003) PTEN signaling pathways in melanoma. Oncogene 22:3113-22
29. Whiteman DC, Zhou XP, Cummings MC, Pavey S, Hayward NK, Eng C (2002) Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int J Cancer 99:63-7
30. Yazdi AS, Palmedo G, Flaig MJ, Puchta U, Reckwerth A, Rutten A et al. (2003) Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 121:1160-2
31. Zhou XP, Gimm O, Hampel H, Niemann T, Walker MJ, Eng C (2000) Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 157:1123-8